Pharmaceuticals · Sales VP · Long Time No Contact
Apology for Pharmaceuticals Sales VP: Long Time No Contact
Use this apology template when you're emailing a Sales VP in Pharmaceuticals (long time no contact). The thread is months old. They may not remember you. You need a reason that belongs to this week, not nostalgia. Keep the note aligned with Crisp and commercial. They can handle a direct ask.
Last updated: 2026-09-02 · Reviewed by: Sales Email Template editors
We write templates the way we wrote emails on quota: short, specific, and easy to forward. When we cite research below, it is because the number changes how a buyer reads your note, not to pad the page.
Sources: HubSpot sales email benchmarks; Gong follow-up research
Why does this apology work for a Pharmaceuticals Sales VP?
- Ask what repair looks like to them instead of guessing.
- Speaks to follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick instead of a generic "value prop."
- Fits how a sales VP actually reads: 70 to 90 words. Lead with the outcome.
- Bring a new observation about their world, then offer a small, optional next step.
- Use 'I' or 'we,' not 'sorry if you were offended.'
When should I send this to a Pharmaceuticals Sales VP?
Send it as soon as you know you were wrong. Delay makes it look calculated. Send when you have a real trigger: news, a useful artifact, a role change, a season. For this combo, treat "Only when you have a trigger" as the default, then adjust around launch calendars and review boards set speed. you don't. If you're emailing a sales VP, 70 to 90 words. Lead with the outcome.
What this Sales VP actually cares about
A sales VP in Pharmaceuticals is protecting quota, forecast credibility, and rep time. They think in pipeline, ramp, and forecast risk. If you can't map your email to a number they already report, it feels like a hobby. The hook that earns a look is a stage in the funnel that's leaking, a slow follow-up SLA, or a ramp problem. The ask should stay at this size: a 15-minute look at one metric, not a platform tour. Delete trigger: Telling them how to sell. They've heard it. a stage in the funnel that's leaking, a slow follow-up SLA, or a ramp problem
How Pharmaceuticals changes the note
Pharmaceuticals buyers are commercial, medical, and ops leads who work under review boards and long timelines. Don't invent clinical claims. Don't treat HCPs like a funnel. If you don't know the rules, your email is a liability. A credible proof point in this vertical sounds like: cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft. Watch the language. Words that land here include MLR, label, access, HCP, congress, promotional review. Proof that lands: cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft.
How should I customize this template before I send it?
- Replace the pain line with an agency waiting on MLR while the sales team keeps asking 'is it approved yet'.
- Keep the tone crisp and commercial.
- Don't CC the world on an apology unless they were affected.
- Time it for Only when you have a trigger. Send when you have a real trigger: news, a useful artifact, a role change, a season.
- Don't use consumer-startup slang. It's a credibility leak.
What mistakes should I avoid with this long time no contact note?
- If you explain more than you apologize, it's not an apology.
- Don't open with 'it's been a while' and then paste the old pitch.
- Don't use consumer-startup slang. It's a credibility leak.
- Telling them how to sell. They've heard it.
How does this long time no contact scenario compare?
| Dimension | For this template |
|---|---|
| Best send window | Only when you have a trigger |
| Ideal length | 70 to 90 words. Lead with the outcome. |
| Primary ask | a 15-minute look at one metric, not a platform tour |
| Industry metric to cite | time through MLR, access, and compliant engagement rates |
| Tone | Crisp and commercial. They can handle a direct ask. |
| Unlike no response | This isn't a 4-day bump. It's a re-introduction with a new reason. |
| Unlike breakup | You're opening a door, not closing one. Still keep it easy to ignore. |
What should I copy and send?
Copy-ready template
Subject
I'm sorry about [specific miss]
Body
Hi [First Name], I'm sorry we [specific miss]. That's on us. In Pharmaceuticals, that usually shows up as follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick. Here's the fix already in motion: [action], owner [name], done by [time]. I won't bury this in process language. Given this is long time no contact, ask if the old problem still exists, or if you should leave it archived. Thank you for the patience I haven't fully earned yet. Best, [Your Name] [Your Title] [Your Company]
Questions people ask before they hit send
Show a leak they recognize: slow follow-up, weak stage conversion, messy handoffs. Ask for a short look at that one number. Don't pitch a philosophy of selling. They already have one, and their forecast is louder than your sequence. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.
Related templates
Want a custom draft instead? Try the email generator.